Abstract
Active surveillance for unknown or unsuspected adverse drug effects may be carried out by applying epidemiological techniques to large administrative databases. Self-controlled designs, like the symmetry design, have the advantage over conventional design of adjusting for confounders that are stable over time. The aim of this paper was to describe the output of a comprehensive open-ended symmetry analysis of a large dataset. All drug dispensings and all secondary care contacts in Denmark during the period 1995–2012 for persons born before 1950 were analyzed by a symmetry design. We analyzed all drug–drug sequences and all drug–disease sequences occurring during the study period. The identified associations were ranked according to the number of outcomes that potentially could be attributed to the exposure. In the main analysis, 29,891,212 incident drug therapies, and 21,300,000 incident diagnoses were included. Out of 186,758 associations tested in the main analysis, 43,575 (23.3%) showed meaningful effect size. For the top 200 drug–drug associations, 47% represented unknown associations, 24% represented known adverse drug reactions, 30% were explained by mutual indication or reverse causation. For the top 200 drug–disease associations the proportions were 31, 15, and 55%, respectively. Screening by symmetry analysis can be a useful starting point for systematic pharmacovigilance activities if coupled with a systematic post-hoc review of signals.
Similar content being viewed by others
References
Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165:1363–9.
Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995;58:108–17.
Waller PC. Making the most of spontaneous adverse drug reaction reporting. Basic Clin Pharmacol Toxicol. 2006;98:320–3.
Moride Y, Haramburu F, Requejo AA, Bégaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol. 1997;43:177–81.
Gaist D, Andersen M, Schou JS. Spontaneous reports of drug-induced erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in Denmark 1968–1991. Pharmacoepidemiol Drug Saf. 1996;5:79–86.
Alvarez-Requejo A, Carvajal A, Bégaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54:483–8.
McCormick TH, Ferrell R, Karr AF, Ryan PB. Big data, big results: knowledge discovery in output from large-scale analytics. Stat Anal Data Min. 2014;7:404–12.
Hallas J, Pottegård A. Use of self-controlled designs in pharmacoepidemiology. J Intern Med. 2014;275:581–9.
Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7:478–84.
Wahab IA, Pratt NL, Wiese MD, Kalisch LM, Roughead EE. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol Drug Saf. 2013;22:496–502.
Wahab IA, Pratt NL, Ellett LK, Roughead EE. Sequence symmetry analysis as a signal detection tool for potential heart failure adverse events in an administrative claims database. Drug Saf. 2016;39:347–54.
Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: The Danish National Prescription Registry. Int J Epidemiol. 2016;46:798.
Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–90.
Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–9.
Thygesen LC, Daasnes C, Thaulow I, Brønnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health. 2011;39:12–6.
Pratt NL, Ilomäki J, Raymond C, Roughead EE. The performance of sequence symmetry analysis as a tool for post-market surveillance of newly marketed medicines: a simulation study. BMC Med Res Methodol. 2014;14:66.
Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf. 2009;18:483–91.
Rothman KJ. Six persistent research misconceptions. J Gen Intern Med. 2014;29:1060–4.
Morris JA, Gardner MJ. Calculating confidence intervals for relative risks, odds ratios, and standardised ratios and rates. In: Gardner MJ, Altman DG, editors. Statistics with confidence. London: British Medical Journal Publishing; 1989. p. 60–1.
Cole DV, Kulldorff M, Baker M, et al. Infrastructure for evaluation of statistical alerts arising from vaccine safety data mining activities in mini-sentinel. https://www.sentinelinitiative.org/sites/default/files/Methods/Mini-Sentinel_PRISM_Data-Mining-Infrastructure_Report_0.pdf.
Gruber S, Chakravarty A, Heckbert SR, Levenson M, Martin D, Nelson JC, et al. Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. Pharmacoepidemiol Drug Saf. 2016;25:973–81.
Bytzer P, Hallas J. Drug-induced symptoms of functional dyspepsia and nausea. A symmetry analysis of one million prescriptions. Aliment Pharmacol Ther. 2000;14:1479–84.
Lorberbaum T, Nasir M, Keiser MJ, Vilar S, Hripcsak G, Tatonetti NP. Systems pharmacology augments drug safety surveillance. Clin Pharmacol Ther. 2015;97:151–8.
Lai ECC, Pottegård A, Lin SJ, Hsieh C-Y, Hallas J, Yang Y-H. Antiepileptic drugs and risk of bacterial infections: a cross-national symmetry analysis from Denmark and Taiwan (submitted).
Harris DG. Management of pain in advanced disease. Br Med Bull. 2014;110:117–28.
Rasmussen L, Hallas J, Madsen KG, Pottegård A. Cardiovascular drugs and erectile dysfunction—a symmetry analysis. Br J Clin Pharmacol. 2015;80:1219–23.
Acknowledgements
Funded by Clinical Pharmacology and Pharmacy, University of Southern Denmark, Denmark and Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, MA, USA.
Author information
Authors and Affiliations
Contributions
JH: Conceived the study, analyzed the data and wrote first draft. SVW, JJG, SS: Conceived the study, provided input to analysis and report. Nicole Pratt: Provided input to analysis and report. Anton Pottegård: Conceived the study, provided input to the report.
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Appendices
Appendix 1
Drug and disease main groups suggestive of confounding by indication. See text for explanation
Drug main group (ATC) | Drug group, plain text | Disease main group (ICD10) | Disease group, plain text |
---|---|---|---|
C | Cardiovascular system | I | Diseases of circulatory system |
D | Dermatologicals | L | Skin diseases |
G | Genito urinary system and sex hormones | N | Genitourinari and renal diseases |
H | Systemic hormonal preparations, excl. sex hormones and insulins | E | Endocrine, nutritional and metabolic diseases |
J | Antiinfectives for systemic use | B | Bacterial and certain viral infections |
J | Antiinfectives for systemic use | A | Viral, fungal and parasitic infections |
L | Antineoplastic and immunomodulating agents | C | Malignant neoplasms |
L | Antineoplastic and immunomodulating agents | D | Benign neoplasms and hematological diseases |
L | Antineoplastic and immunomodulating agents | M | Diseases of the musculoskeletal system and connective tissue |
M | Musculo-skeletal system | M | Diseases of the musculoskeletal system and connective tissue |
P | Antiparasitic products, insecticides and repellents | B | Viral, fungal and parasitic infections |
P | Antiparasitic products, insecticides and repellents | A | Bacterial and certain viral infections |
R | Respiratory system | J | Diseases of respiratory system |
S | Sensory organs | H | Diseases of ear and eye |
Appendix 2
Short description of the data sources included in the study.
The Danish National Prescription Registry contains data on all prescription drugs dispensed to Danish citizens from community pharmacies since 1995. Among other variables, the data include the dispensed substance, the date of dispensing, and quantity dispensed. Dosing information and indication for prescribing are not systematically recorded and were not used for this study. Drugs are categorized according to the Anatomic Therapeutic Chemical (ATC) index, a hierarchical classification system developed by the WHO, and the quantity dispensed for each prescription is given by the number of units and strength of the pharmaceutical product, as well as quantity expressed in the defined daily doses (DDD). The Danish National Prescription Registry does not include medications dispensed during hospitalization.
The Danish National Patient Register contains nationwide data on all non-psychiatric hospital admissions since 1977 and both psychiatric and non-psychiatric outpatient encounters since 1995. Discharge/contact diagnoses have been coded according to ICD-10 since 1994. Diagnoses established in primary care alone, i.e. without any involvement of hospital care, are not captured by the Danish National Patient Register.
The Danish Civil Registration System contains data on date of death and migrations to and from Denmark since 1968, which allowed us to keep track of all subjects during the study period.
Rights and permissions
About this article
Cite this article
Hallas, J., Wang, S.V., Gagne, J.J. et al. Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. Eur J Epidemiol 33, 545–555 (2018). https://doi.org/10.1007/s10654-018-0386-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10654-018-0386-8